CNTB today
$0.69+$0.01 (+0.98%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minAscending Triangle
5 minStrong Bearish
Daily trend turns up above $2.10
Key levels
Resistance$0.89
Resistance$0.73
Support$0.62
Support$0.51
Latest news & SEC filings
AnalystHC Wainwright Reiterates Buy Rating on Connect Biopharma With $7 Price Target
AnalystLeerink Partners starts Connect Biopharma at Outperform with $4 target
All CNTB news →About Connect Biopharma
Connect Biopharma develops antibody-based therapies for breathing disorders, chiefly airway inflammation and the lung condition known as COPD. Its main candidate, rademikibart, targets IL-4Rα and is in mid-stage testing for acute flare-ups of these diseases. The company is headquartered in California and also operates in Australia and China, where Simcere Pharmaceutical holds rights to develop and sell rademikibart in that region.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
Connect Biopharma Holdings Ltd (CNTB)
What Is the Price Target for CNTB?
SEPT Low Target
$4.00
SEPT Mid Target
$5.50
SEPT High Target
$7.00
Analyst Consensus
$5.50
Is CNTB a Buy or Sell Right Now?
Thesis
- •Revenue growing -99.8% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CNTB.
Start Free Trial →Is CNTB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$5.50
10
Moat Score
NONE
1/9
Piotroski Score
-10.8
Altman Z-Score
What Is Smart Money Doing with CNTB?
Insider Signal
NEUTRAL
2 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| LIU JEAN I | director | Buy | 8,984 | - | Sep 30, 2026 |
| Xanthopoulos Kleanthis Gabriel | director | Buy | 5,000 | - | Sep 30, 2026 |
| Huang James | director | Buy | 150,000 | $372K | May 29, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CNTB Growth Story
Revenue YoY
-99.8%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-257.14%
FCF Growth YoY
-112.0%
Revenue Trend
UNKNOWN
Dark Pool Trades for CNTB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CNTB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:31:57 | $0.71 | 1,000 | $$709 | SELL |
| 22:42:09 | $0.68 | 3,802 | $$3K | SELL |
| 20:48:31 | $0.69 | 2,000 | $$1K | BUY |
| 20:42:59 | $0.69 | 14,000 | $$10K | SELL |
| 20:42:59 | $0.70 | 1,100 | $$765 | BUY |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Connect Biopharma Holdings Ltd (CNTB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CNTB — frequently asked questions
What is CNTB stock price today?
Connect Biopharma Holdings Ltd (CNTB) is at $0.69, up 0.98% (+$0.01) at the Nov 11, 2026 close.
Why is CNTB stock moving today?
Latest CNTB news — Oct 28, 2026: HC Wainwright Reiterates Buy Rating on Connect Biopharma With $7 Price Target · Oct 12, 2026: Leerink Partners starts Connect Biopharma at Outperform with $4 target
What is the CNTB price target?
The average analyst price target for CNTB is $5.50, ranging from $4 to $7, based on 6 analysts.
What do analysts rate CNTB?
Analyst ratings for CNTB: 0 Buy, 16 Hold, 0 Sell — consensus Hold.
Did CNTB beat earnings?
CNTB last reported on Aug 12, 2026: EPS -$0.27 vs -$0.31 expected — a beat of 14.3%.
Does CNTB pay a dividend?
CNTB does not currently pay a dividend.
What are CNTB support and resistance levels?
Support: $0.62, $0.51. Resistance: $0.73, $0.89, $1.00.
What are insiders doing with CNTB?
Insider activity: NEUTRAL, 2 buys and 0 sells in the last 90 days.
What is the latest news on CNTB?
Oct 28, 2026: HC Wainwright Reiterates Buy Rating on Connect Biopharma With $7 Price Target · Oct 12, 2026: Leerink Partners starts Connect Biopharma at Outperform with $4 target